GGrantIndex
Sort

48,018 grants matching immunotherapy

Bioinformatics Technology to Characterize Tumor Infiltrating Immune Repertoires

$423,633
Heng Li · Dana-Farber Cancer Inst · U01 · FY2020 · CA

Modulating Immunity through Dendritic Cell Phagocytic Receptors

$423,541
Nina Bhardwaj · New York University School Of Medicine · R01 · FY2008 · AI

Project 2

$423,518
David A Barbie · Dana-Farber Cancer Inst · P50 · FY2025 · CA

Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies

$423,500
Jennetta W Hammond · University Of Rochester · R21 · FY2022 · NS

Defining Mechanisms of Cognitive Dysfunction in Central Nervous System Autoimmunity

$423,500
May Htwe Han · Stanford University · R21 · FY2025 · NS

ELUCIDATION & MODULATION OF NATURAL KILLER CELL SIGNALING: APPLICATION IN CANCER

$423,497
Michael A Caligiuri · Ohio State University · P01 · FY2010 · CA

Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy

$423,486
Dennis O Adeegbe · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2021 · CA

[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors

$423,444
Shivaani Kummar · Stanford University · R01 · FY2020 · CA

Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma

$423,426
Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2024 · CA

Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma

$423,409
Benjamin Aaron Alman · Duke University · R01 · FY2015 · CA

Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells

$423,402
Jianhua Yu · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA

Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels

$423,400
Varghese John · University Of California Los Angeles · R21 · FY2021 · AG

Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma

$423,354
Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2022 · CA

Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma

$423,354
Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2023 · CA

Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma

$423,325
David M Koelle · University Of Washington · P01 · FY2023 · CA

Mechanisms of the Induction of Oral Tolerance

$423,324
Howard L Weiner · Brigham And Women'S Hospital · R01 · FY2011 · AI

Metabolism-based interactions and organ-targeted delivery of molnupiravir, nirmatrelvir and remdesivir

$423,312
Bingfang Yan · University Of Cincinnati · R01 · FY2023 · AI

Impact of Genetic Diversity on Human Xenograft Tumor Growth

$423,300
Muneer Gulamhusein Hasham · Jackson Laboratory · R33 · FY2021 · CA

Impact of Genetic Diversity on Human Xenograft Tumor Growth

$423,298
Muneer Gulamhusein Hasham · Jackson Laboratory · R33 · FY2020 · CA

Isoprenylcysteine Carboxyl Methyltransferase (ICMT) as a Target in NRAS Driven Melanoma - Resubmission - 1

$423,242
Mark Reid Philips · New York University School Of Medicine · R01 · FY2019 · CA

Isoprenylcysteine Carboxyl Methyltransferase (ICMT) as a Target in NRAS Driven Melanoma - Resubmission - 1

$423,242
Mark Reid Philips · New York University School Of Medicine · R01 · FY2020 · CA

Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature

$423,186
Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · CA

Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature

$423,186
Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · CA

Defining therapeutic strategies for boosting T-cell infiltration into cold tumors with spatial proteomics and machine learning

$423,078
Matthew W. Thomson · California Institute Of Technology · R21 · FY2023 · CA

Mechanisms of Immune-mediated Tumor Cell Destruction

$423,078
Thomas Sayers · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA